XL550
drugOn this page
Also known as CS-3150EsaxerenoneXL-550
Summary
Xl550 (CHEMBL3545393) is a phase-3 clinical-stage unknown; indicated across 4 conditions including hypertensive disorder and hyperaldosteronism.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 4 conditions
- Clinical trials: 11
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545393 |
| Name | XL550 |
| Type | Unknown |
| Max phase | 3 |
Also known as: CS-3150, Esaxerenone, XL-550, Xl550, XL550
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| hyperaldosteronism | 3 | MONDO:0003009 | MONDO:0001422 |
| essential hypertension | 3 | MONDO:0001134 | MONDO:0001134 |
| diabetic kidney disease | 2 | MONDO:0005016 | EFO:0000401 |
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 5 |
| PHASE2 | 3 |
| Not specified | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02722265 | PHASE3 | COMPLETED | Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension |
| NCT02807974 | PHASE3 | COMPLETED | Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria |
| NCT02807987 | PHASE3 | COMPLETED | Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment |
| NCT02808026 | PHASE3 | COMPLETED | Study of CS-3150 in Patients With Severe Hypertension |
| NCT02890173 | PHASE3 | COMPLETED | Study of CS-3150 in Patients With Essential Hypertension |
| NCT02345044 | PHASE2 | COMPLETED | A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects |
| NCT02345057 | PHASE2 | COMPLETED | A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria |
| NCT02448628 | PHASE2 | COMPLETED | A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment |
| NCT04019652 | PHASE1 | COMPLETED | The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers |
| NCT02848170 | Not specified | COMPLETED | Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension |
| NCT02885662 | Not specified | COMPLETED | Study of CS-3150 in Patients With Primary Aldosteronism |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).